Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Mitochondria-Targeting pill help failing hearts?

NCT ID NCT05410873

Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether MitoQ, a drug that targets cell energy centers, can improve heart function in 53 people with dilated cardiomyopathy. Participants took MitoQ or a placebo for several months while researchers measured heart energy levels and pumping ability using MRI scans. The goal was to see if reducing cell stress could help the heart work better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MitoQ (mitoquinol mesylate)
What this could lead to
If it works, this could point toward a new treatment that helps the heart work better in people with dilated cardiomyopathy.
What could go wrong
This is a small, early-phase trial with only 53 participants, so results may not apply to everyone. The drug may not improve heart function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

53 people

The number who actually took part.

Started

Jul 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. idiopathic or familial DCM 2. LVEF ≤45% on 2 imaging studies of any modality ≥3 months apart (may include CMR scan at baseline visit) 3. on guideline therapy for ≥3 months as determined by usual clinicians 4. sinus rhythm on 12-lead electrocardiogram 5. plasma NT-pro-BNP \>250ng/L for those \>65 years and \>100ng/L for those aged ≤65 years within the last 6 months (may include sample at baseline visit) Exclusion criteria 1. current persistent atrial fibrillation 2. contraindication to CMR 3. estimated glomerular filtration rate (eGFR) \<30mls/min 4. current or planned pregnancy or current breast-feeding 5. clear environmental trigger such as excess alcohol intake, cardiotoxic chemotherapy or peripartum presentation 6. fibrosis burden \>25% on CMR 7. current cancer (other than non-melanoma skin cancers) 8. current use of CoQ10 9. current participation in another randomised controlled trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dilated cardiomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dilated cardiomyopathy

Contacts and locations

Locations

  • Royal Brompton Hospital

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.